Claremedica replaced paper-based cognitive screening with digital assessment and identified over 90% of new dementia cases at early stages, compared to the 60% national rate of missed cognitive impairment in primary care. The shift captured earlier-stage decline that traditional screeners routinely miss, enabling intervention while therapeutic options remain viable.
Key Points
- Digital cognitive assessment caught 90% of new dementia at early stage
- 80% of newly identified cases had failed traditional screening previously
- Screening time reduced from 12 to 6 minutes, improving workflow efficiency
Longevity Analysis
Cognitive decline progresses subtly and is often the only vital sign not systematically monitored in primary care, creating a critical gap in early detection. By replacing coarse pass-fail tools with domain-level cognitive profiling that measures memory, attention, reasoning, and executive function separately, clinicians can now decode the body's signals before decline becomes irreversible. The speed and accessibility of the new tool—six minutes, tablet-based, requiring no physician supervision—removes friction from implementation, making consistent execution of cognitive screening feasible across diverse patient populations and clinical settings.
Original published by Longevity.Technology, by Kyle Umipig.